VERAXA Biotech debuts on Nasdaq with $77.5M to target solid tumors

VERAXA Biotech begins trading on Nasdaq after closing its SPAC merger, armed with $77.5M to advance its BiTAC platform against solid tumors.

VERAXA Biotech AG starts trading on Nasdaq on June 11 after completing its merger with Voyager Acquisition Corp., bringing a novel dual-targeting platform for solid tumors that could expand the therapeutic window for bispecific antibodies.

"The completion of our business combination better positions us to deliver meaningful value to patients with cancer," Christoph Antz, Ph.D., Chief Executive Officer of VERAXA, said.

The company secured $27.5M in senior secured notes and a $50M share purchase agreement. At the AACR 2026 Annual Meeting in San Diego, VERAXA presented data showing its lead BiTAC-TCE candidate attacked cancer cells expressing both target antigens while sparing cells with only one — a safety profile the company says exceeds traditional T-cell engagers.

VERAXA's BiTAC platform targets solid tumors, a market where bispecific T-cell engagers have historically struggled due to on-target, off-tumor toxicity. If the dual-antigen approach translates in the clinic, it could unlock a multibillion-dollar opportunity in non-exclusive cancer markers that current therapies cannot safely address.

How BiTAC Differs from Standard TCEs

Bispecific T-cell engagers work by binding one arm to a tumor antigen and the other to a T-cell, forcing an immune attack. The problem: many solid-tumor antigens also appear on healthy tissue, causing dose-limiting toxicities. VERAXA's BiTAC platform requires two tumor antigens to be present simultaneously — an AND-gate logic — before activating the T-cell. This conditional activation is designed to spare healthy cells that express only one of the targets.

The AACR data showed the BiTAC-TCE candidate matched the efficacy of a conventional TCE in vitro and in vivo while demonstrating a superior safety profile. VERAXA did not disclose the specific antigens or the comparator TCE used in the study.

The platform also extends beyond T-cell engagers. VERAXA is developing BiTAC-enabled antibody-drug conjugates and says the technology can be applied to radioimmunoconjugates and antibody-oligonucleotide conjugates, broadening its addressable pipeline.

Pipeline and Financial Runway

VERAXA's pipeline focuses on solid tumors, with its most advanced program in the BiTAC-TCE class. The company has not disclosed which programs will enter the clinic first or the expected timeline for Investigational New Drug filings. The $77.5M in combined financing — $27.5M in senior secured notes and up to $50M via a securities purchase agreement — is intended to advance programs through initial value inflection points, though VERAXA has not specified a cash runway date.

The company was founded on scientific breakthroughs from the European Molecular Biology Laboratory, a life sciences research institute based in Heidelberg, Germany. Xlife Sciences AG, a Swiss incubator and accelerator, holds a significant ownership stake, with CEO Oliver R. Baumann serving as VERAXA's Chairman.

Competitive Landscape

VERAXA enters a crowded bispecific antibody field dominated by companies including Amgen Inc., whose Blincyto was the first FDA-approved BiTE, and Roche Holding AG, which markets Lunsumio and Columvi for hematologic cancers. Most approved T-cell engagers target blood cancers, not solid tumors. Immunocore Holdings plc has shown solid-tumor activity with its ImmTAC platform, though it uses a different mechanism.

The key differentiator for VERAXA is the AND-gate logic, which could enable targeting of antigens that are overexpressed on tumors but also present on normal tissue — a class of targets currently considered undruggable with conventional bispecifics. If clinical data confirm the preclinical safety signal, VERAXA could address a broader set of solid-tumor indications than existing TCE platforms.

VERAXA's common stock begins trading June 11 under the ticker VRXA on the Nasdaq Capital Market. Warrants trade under VRXAW.

This article is for informational purposes only and does not constitute investment advice.